Syngene

 Bangalore, Mar, 23, 2010: Syngene International, a subsidiary of Biocon has entered into a discovery and development collaboration with Endo Pharmaceuticals, USA to develop novel biological therapeutic molecules against cancer.

Under the agreement Endo will retain all rights to the molecules developed, while Syngene International will receive research fees, milestone payments and success fees from Endo.